Practical Geriatrics ›› 2022, Vol. 36 ›› Issue (10): 1058-1061.doi: 10.3969/j.issn.1003-9198.2022.10.020
Previous Articles Next Articles
Received:2021-10-01
Online:2022-10-20
Published:2022-10-21
CLC Number:
| [1] RUSSO G I, CIMINO S, CASTELLI T, et al. Benign prostatic hyperplasia, metabolic syndrome and non-alcoholic fatty liver disease: is metaflammation the link[J]. Prostate, 2016, 76(16): 1528-1535. [2] RODERFELD M. Matrix metalloproteinase functions in hepatic injury and fibrosis [J] Matrix Biol, 2018, 68-69:452-462. [3] VAN METER E N, ONYANGO J A, TESKE K A. A review of currently identified small molecule modulators of microRNA function[J]. Eur J Med Chem, 2020, 188:1-24. [4] HATA A, KASHIMA R. Dysregulation of microRNA biogenesis machinery in cancer[J]. Crit Rev Biochem Mol Biol, 2016, 51(3):121-134. [5] BANDIERA S, PFEFFER S, BAUMERT T F, et al. miR-122--a key factor and therapeutic target in liver disease[J]. J Hepatol, 2015, 62(2):448-457. [6] BENZ F, ROY S, TRAUTWEINN C, et al. Circulating microRNAs as biomarkers for sepsis[J]. Int J Mol Sci, 2016, 17(1):78. [7] KAUR N, GOYAL G, GARG R, et al. Potential role of noninvasive biomarkers during liver fibrosis[J]. World J Hepatol, 2021, 13(12):1919-1935. [8] TREBICKA J, ANADOL E, ELFIMOVA N, et al. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis[J]. J Hepatol, 2013, 58(2):234-239. [9] SCHUPPAN D, KIM Y O. Evolving therapies for liver fibrosis[J]. J Clin Invest, 2013, 123(5):1887-1901. [10] LEE U E, FRIEDMAN S L. Mechanisms of hepatic fibrogenesis[J]. Best Pract Res Clin Gastroenterol, 2011, 25(2):195-206. [11] WANG R, DING Q, YAQOOB U, et al. Exosome adherence and internalization by hepatic stellate cells triggers sphingosine 1-phosphate-dependent migration[J]. J Biol Chem, 2015, 290(52):30684-30696. [12] MATSUURA K, DE GIORGI V, SCHECHTERLY C, et al. Circulating let-7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C[J]. Hepatology, 2016, 64(3):732-745. [13] LEE Y S, KIM S Y, KO E, et al. Exosomes derived from palmitic acid-treated hepatocytes induce fibrotic activation of hepatic stellate cells[J]. Sci Rep, 2017, 7(1):3710. [14] POVERO D, PANERA N, EGUCHI A, et al. Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic stellate cell via microRNAs targeting PPAR-gamma[J]. Cell Mol Gastroenterol Hepatol, 2015, 1(6):646-663, e644. [15] HYUN J, WANG S, KIM J, et al. MicroRNA-378 limits activation of hepatic stellate cells and liver fibrosis by suppressing Gli3 expression[J]. Nat Commun, 2016, 22(7):10993. [16] LUO X, XU Z X, WU J C, et al. Hepatocyte-derived exosomal miR-27a activateshepatic stellate cells through the inhibitionof PINK1-mediated mitophagy in MAFLD[J]. Mol Ther Nucleic Acids, 2021, 26:1241-1254. [17] ZHANG L, LIU C, MENG X M, et al. Smad2 protects against TGF-beta1/Smad3-mediated collagen synthesis in human hepatic stellate cells during hepatic fibrosis[J]. Mol Cell Biochem, 2015, 400(1/2):17-28. [18] LAN H Y, CHUNG A C. Transforming growth factor-β and Smads[J]. Contrib Nephrol, 2011, 170:75-82. [19] WEI S, WANG Q, ZHOU H, et al. miR-455-3p alleviates hepatic stellate cell activation and liver fibrosis by suppressing HSF1 expression [J]. Mol Ther Nucleic Acids, 2019,16:758-769. [20] TU X, ZHANG H, ZHANG J, et al. MicroRNA-101 suppresses liver fibrosis by targeting the TGFβ signalling pathway[J]. J Pathol, 2014, 234(1):46-59. [21] LAKNER A M, STEUERWALD N M, WALLING T L, et al. Inhibitory effects of microRNA 19b in the patic stellate cell-mediated fibrogenesis[J]. Hepatology, 2012, 56(1): 300-310. [22] ROY S, BENZ F, VARGAS C D, et al. miR-30c and miR-193 are a part of the TGF-β-dependent regulatory network controlling extracellular matrix genes in liver fibrosis[J]. J Dig Dis, 2015, 16(9): 513-524. [23] SHU M, HUANG D D, HUNG Z A, et al. Inhibition of MAPK and NF-κB signaling pathways alleviate carbon tetrachloride (CCl4)-induced liver fibrosis in Toll-like receptor 5 (TLR5) deficiency mice[J]. Biochem Biophys Res Commun, 2016, 471(1):233-239. [24] FENG X, TAN W, CHENG S, et al. Upregulation of microRNA-126 in hepatic stellate cells may affect pathogenesis of liver fibrosis through the NF-κB pathway[J]. DNA Cell Biol, 2015, 34(7):470-480. [25] WANG J, CHU E S, CHEN H Y, et al. microRNA-29b prevents liver fibrosis by attenuating hepatic stellate cell activation and inducing apoptosis through targeting PI3K/AKT pathway[J]. Oncotarget, 2015, 6(9):7325-7338. [26] MATSUDA S, KOBAYASHI M, KITAGISHI Y. Roles for PI3K/AKT/PTEN pathway in cell signaling of nonalcoholic fatty liver disease[J]. ISRN Endocrinol, 2013, 2013:472432. [27] SAITO-DIAZ K, CHEN T W, WANG X, et al. The way Wnt works: eomponents and mechanism[J]. Growth Factors, 2013, 31(1):1-31. [28] YU F, LU Z, HUANG K, et al. MicroRNA-17-5p-activated Wnt/β-catenin pathway contributes to the progression of liver fibrosis[J]. Oncotarget, 2016, 7(1):81-93. [29] VAN ROOIJ E, SUTHERLAND L B, Thatcher T J, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis[J]. Proc Natl Acad Sci USA, 2008, 105(35): 13027-13032. [30] RODERBURG C, URBAN G W, BETTERMANN K, et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis[J]. Hepatology, 2011, 53(1): 209-218. [31] ANDO Y, YANG G X, KENNY T P, et al. Overexpression of microRNA-21 is associated with elevated proinflammatory cytokines in dominant-negative TGF-β receptor type II mouse[J]. J Autoimmun, 2013, 41:111-119. [32] LI W Q, CHEN C, XU M D, et al. The rno-miR-34 family is upregulated and targets acsl1 in dimethylnitrosamine-induced hepatic fibrosis in rats[J]. FEBS J, 2011, 278(9): 1522-1532. [33] YAN G, LI B, XIN X, et al. MicroRNA-34a promotes hepatic stellate cell activation via targeting ACSL1[J]. Med Sci Monit, 2015, 21: 3008-3015. [34] BALA S, CSAK T, SAHA B, et al. The pro-inflammatory effects of miR-155 promote liver fibrosis and alcohol-induced steatohepatitis[J]. J Hepatol, 2016, 64(6):1378-1387. [35] TREBICKA J, ANADOL E, ELFIMOVA N, et al. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis[J]. J Hepatol, 2013, 58(2): 234-239. [36] ZENG C, WANG Y L, XIE C, et al. Identification of a novel TGF-β-miR-122-fibronectin 1/serum response factor signaling cascade and its implication in hepatic fibrogenesis[J]. Oncotarget, 2015, 6(14): 12224-12233. [37] LAKNE M, STEUERWALD M, WALLING L,et al. Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis[J]. Hepatology, 2012, 56(1): 300-310. [38] RODERBURG C, MOLLNOW T, BONGAERTS B, et al. Micro-RNA profiling in human serum reveals compartment-specific roles of miR-571 and miR-652 in liver cirrhosis[J]. PLoS One, 2012,7(3):e32999. [39] ABDEL-AL A, EL-AHWANY E, ZOHEIRY M, et al. miRNA-221 and miRNA-222 are promising biomarkers for progression of liver fibrosis in HCV Egyptian patients[J]. Virus Res, 2018, 253:135-139. [40] OGAWA T, ENOMOTO M, FUJII H, et al. MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis[J]. Gut, 2012, 61(11): 1600-1609. |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
|
